Inhibition of collagenolytic activity relates to quantitative reduction of invasion in vitro in a c-Ha-ras transfected glial cell line.
The function of proteases in brain tumor invasion is currently not well established. For tumors of epithelial and fibromatous origin collagenase production can enhance the invasive capacity of cells to penetrate basement membranes. We showed previously that a c-Ha-ras transformed glial cell line (CxT24neo3) invaded hamster brain tissue in vivo. These cells were also capable of invading reconstituted basement membrane and embryonic chick hearts in vitro. Since the histopathology of CxT24neo3 tumors mimics that of glioblastoma multiforme in humans, CxT24neo3 was used as the model in vitro for this type of brain tumor. Presently, we detected by zymogram analysis a gelatinase that was secreted by CxT24neo3 and that had an apparent molecular mass of 62 kD. To verify whether gelatinase affected invasion in vitro of these glial cells we determined the efficacy of a substrate specific collagenase inhibitor on invasion in vitro. GM6001 is a synthetic polypeptide that specifically occupies the substrate binding sites of metalloprotease. Since this drug did not show cytotoxicity, its specificity for metalloprotease is a valuable tool to evaluate the physiological function of these enzymes on invasion. We found that treatment of CxT24neo3 with GM6001 reduced the fraction of invading CxT24neo3 cells through reconstituted basement membrane. These data suggest that metalloproteases can stimulate brain tumor invasion.
Boghaert
E R
ER
University of Kentucky, Dept. of Surgery, Markey Cancer Center, Lexington.
Chan
S K
SK
Zimmer
C
C
Grobelny
D
D
Galardy
R E
RE
Vanaman
T C
TC
Zimmer
S G
SG
D000577:Amides / Q000494:pharmacology*; D000818:Animals; D001485:Basement Membrane / Q000473:pathology; D002461:Cell Line, Transformed; D002465:Cell Movement / Q000187:drug effects; D002642:Chick Embryo; D003094:Collagen; D006224:Cricetinae; D017077:Culture Media, Conditioned / Q000737:chemistry; D016895:Culture Media, Serum-Free; D004151:Dipeptides / Q000494:pharmacology*; D004338:Drug Combinations; D018093:Gelatinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006321:Heart / Q000196:embryology; D007797:Laminin; D008647:Mesocricetus; D009206:Myocardium / Q000473:pathology; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009457:Neuroglia / Q000201:enzymology / Q000473:pathology*; D011480:Protease Inhibitors / Q000494:pharmacology*; D011509:Proteoglycans; D016283:Proto-Oncogene Proteins p21(ras) / Q000502:physiology*; D011993:Recombinant Fusion Proteins; D014162:Transfection; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000577:Amides; D017077:Culture Media, Conditioned; D016895:Culture Media, Serum-Free; D004151:Dipeptides; D004338:Drug Combinations; D007797:Laminin; C078131:N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D011509:Proteoglycans; D011993:Recombinant Fusion Proteins; C065557:N-(2-isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; C059485:matrigel; D014443:Tyrosine; D003094:Collagen; D018093:Gelatinases; D016283:Proto-Oncogene Proteins p21(ras)